EMG
LFCR icon

Ellington Management Group’s Lifecore Biomedical LFCR Stock Holding History

Ellington Management Group’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-17,000
Closed -$225K – 888
2013
Q2 		$225K Buy
+17,000
New +$235K 0.04% 629

Other funds holding LFCR

GC
Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
OCG
Opus Capital Group Cincinnati, Ohio $930M AUM 16.14% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
KG
Killen Group Berwyn, Pennsylvania $866M AUM 0.25% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ellington Management Group's LFCR Position: Q3 2013 in Review

Ellington Management Group sold out of Lifecore Biomedical (LFCR) in Q3 2013, closing a stake of 17,000 shares — an estimated $225K sold.

Ellington Management Group first reported a position in LFCR in Q2 2013 and held it in 1 quarter. The position peaked at $225K in Q2 2013. 125 funds tracked by Wall St. Rank hold LFCR as of Q3 2013.

  • Ellington Management Group reported no remaining Lifecore Biomedical position as of Q3 2013 after selling out during the quarter.
  • Ellington Management Group sold 17,000 Lifecore Biomedical shares in Q3 2013, an estimated $225K.
  • Ellington Management Group first reported a position in Lifecore Biomedical in Q2 2013 and held it in 1 quarter.
  • Ellington Management Group's Lifecore Biomedical position peaked at $225K in Q2 2013.
  • 125 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2013.

Based on Ellington Management Group's 13F filing for Q3 2013, filed 14 Nov 2013.